Customers We Serve
Imagine Biotech collaborates with early to mid-stage biotech companies, therapeutic founders, and life science investors who are developing novel small molecules or biologics.
In traditional drug discovery, millions are often spent progressing compounds into preclinical models, only to arrive at a “No” due to poor solubility, metabolic instability, off-target toxicity, or suboptimal pharmacodynamics. We help teams reach those answers faster, and at a fraction of the cost, through in silico methods.
​
By applying advanced computational chemistry, quantum mechanical modeling, and molecular dynamics simulations, we generate mechanistic insight into compound behavior, drug-target interactions, and ADMET profiles before a single in vivo study is run.
Our work supports rational compound selection, lead optimization, and IP development — enabling more strategic resource allocation and scientifically grounded go/no-go decisions. For investors, we reduce technical risk and surface high-conviction opportunities earlier in the discovery process.
" There is solid evidence for R&D process improvements that can be achieved by using modelling, with a return of investment in the range of 3:1 to 9:1. "
1
Venture Capital | Family Offices | Private Investors
We support investors with advanced scientific due diligence to reduce risk and improve capital efficiency in early stage biotech. Using computational chemistry, molecular modeling, and in silico ADMET prediction, we identify red flags, such as poor solubility, metabolic instability, or weak drug target interactions, before costly lab or animal studies begin. We deliver this insight through sophisticated, data driven reports prepared by our internal team of PhD experts. These reports help investors avoid false positives, accelerate go or no go decisions, and build stronger conviction with limited partners. In a cautious funding environment, we bring clarity, precision, and confidence to life science investing.
2
Startups | Founders
We partner with therapeutic founders to accelerate discovery, reduce technical risk, and preserve capital during the most critical stages of drug development. Early stage programs often commit millions to lab work and animal studies before fully understanding their molecule’s limitations.
We offer a smarter approach using computational chemistry, quantum modeling, and in silico profiling, we generate deep mechanistic insights into drug behavior, from solubility and metabolic stability to enzyme binding and toxicity, in the early stages, when a clear understanding of your molecule is essential to build the confidence of investors.
Our internal team of PhD scientists delivers this in the form of sophisticated, decision-ready reports, helping founders make faster, data backed choices, strengthen IP strategy, and tell a more compelling scientific story when raising capital or pursuing partnerships.
3
Tech Transfer Academic Institutions
We partner with academic institution tech transfer offices to help bring their innovations to market. By providing detailed scientific analysis and commercialization strategies, we ensure patents are thoroughly evaluated and positioned as investable opportunities. Our expertise helps institutions maximize the potential of their discoveries, transforming early-stage ideas into viable, market-ready assets.
GlycoMira Therapeutics, Inc.
" GlycoMira is developing a first-in-class bi-modal immune modulating anti-tumor therapeutic that has the potential the establish a new paradigm for the treatment of solid tumors.
​
The data from Imagine Biotech using sophisticated technologies on our lead drug candidate will greatly accelerate our clinical development program and reduce risk as we move forward with first in human clinical investigations.
​
Imagine Biotech's risk reduction tools should be considered essential for any drug development company.
- Sincerely,"
Dr. William Tew (CEO)
Get in touch with us through our contact form; we're here and ready to discuss possibilities in a different light.